GOCO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GOCO is not a good buy right now for a beginner long-term investor. The stock is trading at 1.13 pre-market, but the technical picture is weak, the latest quarter financials collapsed, analysts are turning cautious, and there are no strong proprietary buy signals. Given the user's willingness to deploy $50,000-$100,000 now and unwillingness to wait for an ideal entry, the direct call is to avoid buying and not commit capital here.
Current trend is bearish. MACD histogram is slightly positive and expanding, which shows a small near-term momentum improvement, but it is not enough to offset the broader structure. RSI at 43.47 is neutral-to-weak, not oversold enough to signal a strong rebound. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, confirming a downtrend. Price is below the pivot at 1.195 and only slightly above support at S1 1.086, so the stock is trading near weak support rather than breaking out. Similar-pattern trend data also points to soft forward returns over the next week and month.
No news in the recent week means there are no immediate event-driven positives. The only minor positive is the slightly improving MACD histogram, which suggests short-term downside momentum may be easing. Pre-market price holding near support can also be viewed as a possible stabilization point.
The analyst cited a 97% year-over-year revenue drop in Q4 and weak Medicare Advantage commission economics, with a cautious view on 2026 and rebound hopes pushed to
Financials are extremely weak: Q4 revenue fell to 12.64M, net income dropped to -33.60M, EPS fell to -2.09, and gross margin also declined. There was no recent news catalyst, no meaningful hedge fund or insider accumulation, no congress trading activity, and no significant proprietary buy signal today.
In 2025/Q4, GoHealth reported a severe deterioration in results. Revenue fell 96.75% year over year to 12.64M, net income declined to -33.60M, EPS dropped to -2.09, and gross margin contracted to 65.59. This indicates a major decline in growth and profitability in the latest reported quarter.
Recent analyst sentiment is negative. Freedom Broker downgraded GoHealth to Hold from Buy on 2026-04-06 and cut the price target from $4.50 to $1.50. The firm highlighted weak Q4 revenue, deteriorating Medicare Advantage commission economics, and a weak outlook for 2026. Wall Street pros appear cautious rather than bullish, with few visible upside arguments at the moment and clear concerns about revenue collapse and execution.
